Biomarkers in Oncology – Access & Reimbursement – Detailed, Expanded Analysis: Biomarkers in Oncology – NSCLC, Bladder Cancer, and Gastric / GEJ Adenocarcinoma (US)
Biomarker-driven prescribing is paramount in key oncology indications. The use of biomarkers is entrenched in indications such as non-small-cell lung cancer (NSCLC) and bladder cancer and is playing an increasingly important role in indications such as gastric and gastroesophageal junction (GEJ) adenocarcinoma. Although biomarker-associated therapies offer the advantage of selecting the patients most likely to respond to treatment, these therapies are premium-priced and often subject to payer restrictions and cost-containment strategies.
QUESTIONS ANSWERED
· What factors largely influence payers’ reimbursement decisions for biomarker-driven therapies in NSCLC, bladder cancer, and gastric and GEJ adenocarcinoma? What restrictions do they impose?
· Do access and reimbursement challenges differ by indication, and how well established are biomarkers in each indication?
· What impact do reimbursement and cost have in oncologists’ decisions to prescribe biomarker-driven therapies?
· What are payer opinions of emerging agents, and how will oncologists’ prescribing patterns change with the launch of new therapies?
· What factors influence reimbursement and access of companion biomarker tests?
GEOGRAPHY: United States.
PRIMARY RESEARCH: Survey of 100 U.S. medical oncologists and 30 U.S. managed care organization (MCO) pharmacy directors and medical directors (PDs/MDs).
KEY DRUGS COVERED:
Tagrisso, Tarceva, Gilotrif, Iressa, Vizimpro, Rybrevant, Lumakras, Tabrecta, Tepmetko, Retevmo, Gavreto, Keytruda, Tecentriq, Balversa, Opdivo, and Enhertu
CONTENT HIGHLIGHTS:
- Reimbursement and contracting
- Access and prescribing
- Opportunities and challenges for emerging therapies
- Disease-specific special topic
Table of contents
- Biomarkers in Oncology - Access & Reimbursement - Detailed, Expanded Analysis: Biomarkers in Oncology - NSCLC, Bladder Cancer, and Gastric / GEJ Adenocarcinoma (US)
- Access & Reimbursement | Biomarkers in Oncology | US | December 2021
- Biomarker-Driven Prescribing in Non-Small-Cell Lung Cancer (NSCLC), Bladder Cancer, and Gastric or GEJ Adenocarcinoma | Access and Reimbursement | United States
- Biomarker-Driven Prescribing in Non-Small-Cell Lung Cancer (NSCLC), Bladder Cancer, and Gastric or GEJ Adenocarcinoma | Access and Reimbursement | United States-1
Saurabh Virdi, B.Tech., Lead Healthcare Research & Data Analyst, Oncology. Mr. Virdi has more than seven years working in the pharmaceutical industry providing analytical support in various therapy areas, including oncology, HIV, vaccines, specialty pharma, and rare diseases. Prior to joining Clarivate, he was an assistant project manager at DelveInsight Business Research LLP, where he was responsible for developing and delivering customized market and asset value forecasts. Before DelveInsight, he worked at WNS GSK Knowledge center and SmartAnalyst, where, as part of multifunctional teams, he helped clients’ decision making throughout the development journey from early-stage to marketed drugs. He obtained his bachelor’s degree in biotechnology from Delhi Technological University in India.
Chris Lewis, Lead Healthcare Research & Data Analyst, U.S. Access and Reimbursement. Ms. Lewis oversees Clarivate’s U.S. Access & Reimbursement reports, including managing the primary research activities, reviewing content, and authoring select A&R reports on managed care trends. A Clarivate employee for 16 years, Ms. Lewis previously was a senior analyst who authored Health Plan Analysis reports and PBM profiles. She received her bachelor’s degree from California State University in Sacramento.
